Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

NIDA Home > Publications > Director's Reports > February, 2010 Index    

Director's Report to the National Advisory Council on Drug Abuse - February, 2010



Publications

NIDA Publications

NIDA Publishes New Mind Over Matter
In response to the growing problems with abuse of prescription drugs, NIDA has just published a new Mind Over Matter on Prescription Drugs. The 9th in the Mind Over Matter series, this publication explores how prescription drugs act in the brain in a colorful and engaging manner appropriate for middle school children.

NIDA Reprints "Brain Power! NIDA Junior Scientists"
NIDA has updated and reprinted it's highly successful program for kindergarten and first grade, "Brain Power! NIDA Junior Scientists". This publication provides teachers with lesson that span a week and cover the brain and how to keep it healthy.

Epidemiologic Trends in Drug Abuse Highlights and Executive Summary
June 2009, Volume I -- NIH Pub. No. 10-7421 (Print Date TBD)

This report provides descriptive information on the most recent significant trend, emerging problems and populations at risk within and across areas participating in the Community Epidemiology Work Group. This report provides program administrators and officials with specific indicator data in tabular and graphic format, and ethnographic information on current patterns and trends as well as emerging problems.

Epidemiologic Trends in Drug Abuse Highlights and Executive Summary
June 2009, Volume II -- NIH Pub. No. 10-7422 (Print Date TBD)

This volume contains the edited research reports submitted by the Work Group participants. It provides an in-depth analysis of the epidemiologic trends and special reports for a limited audience made up primarily of drug abuse researchers who utilize this volume to identify potential areas for further research.

Research Report Series: Tobacco Addiction (Spanish) NIH Pub. No. 10-4342(S) (Print Date TBD)
This report describes what tobacco is, presents current epidemiological research data regarding its use, and reports on the medical consequences of tobacco use. It emphasizes the effects on the brain as well as current research findings about use during pregnancy. It also includes treatment approaches.

Research Report Series: Cocaine Abuse (Spanish) NIH Pub. No. 10-4166(S) (Print Date TBD)
This updated version contains scientific information on crack and cocaine. Facts based on the latest technology are used to describe the different effects of this drug; as well as the pathways in the brain that it affects; the medical consequences of use; and some behavioral treatments for cocaine abuse. NIDA also reports on several pharmacological compounds currently being tested for their potential use in treating cocaine addiction.

Principles of Drug Addiction Treatment: A Research-Based Guide (Rev.) (Spanish)
NIH Pub. No.: 10-4180(S) (Print Date TBD)

This guide will communicate the latest research-based information about the treatment of drug addiction to a vast audience. In question and answer format this guide explains the various treatment approaches developed through NIDA-supported research and helps to explain some of the medical, social, and economic benefits associated with drug addiction treatment.

NIDA NOTES

NIDA NOTES, Vol. 22, No. 4 - NIH Pub. No.09-6459
The lead story reports data identifying chromosome sites linked with nicotine addiction in two racial groups. The issue also features a mouse model for mania; a program that reduces girls' delinquent behavior; evidence that a dopamine receptor complex triggers cellular signaling; and an intervention that shows long-term benefits in children with disruptive behavior disorder. The Director's Perspective emphasizes the importance of treating addiction as a chronic disease.

NIDA NOTES, Vol. 22, No. 5 - NIH Pub. No. 09-6460
The lead story describes how computer-based interventions can promote drug abstinence by reinforcing and expanding the well-established benefits of therapy delivered by a counselor. The story presents three groundbreaking examples of interactive multimedia therapies that may reduce costs and extend access to treatment. Also included in the issue are features reporting an immunotherapy that shows promise as a treatment for methamphetamine overdose; evidence that a person's genetic makeup influences success in quitting smoking and also which smoking cessation technique works best; and a new technique that uses dime-size arrays of tiny needles to painlessly deliver naltrexone and other medications. Another feature explores how extended cocaine exposure impairs attention in rats. In the Director's Perspective, Dr. Nora Volkow describes NIDA coalition with other federal agencies to assess and find solutions to the problems of substance abuse among service men and women, veterans, and members of military families.

NIDA NOTES, Vol. 22, No. 6 - NIH Pub. No. 10-7440
This issue begins with a description of research from several laboratories that links contrasting smoking patterns with variations in half a dozen genes that dictate the structure of the brain receptor to which nicotine binds. The results suggest that genes for several receptor subunits drive different aspects of the multi-step process of nicotine addiction. Also included in the issue is a feature reporting that a checkup system provided after treatment for substance abuse may be especially beneficial for clients with co-occurring mental disorders. Another feature presents evidence that highly active antiretroviral therapy (HAART) is as useful in combating HIV in people who use illicit injection drugs as in other people infected with the virus. The issue also includes a report that proliferation of a rare receptor may underlie the intensification of craving that cocaine abusers experience during their first weeks of abstinence. In the Director's Perspective, Dr. Nora Volkow notes NIDA's 35th Anniversary, listing the Institute's major accomplishments and describing current challenges.

CTN-Related Publications

Seven editions of the CTN Bulletin Board were distributed. The Bulletin Board is an electronic report on the progress of the protocols, committees, and node activity in the CTN. The Bulletin has wide readership within and outside the CTN and NIDA.

Data from 20 CTN trials are now available on the CTN Data Sharing Web Site http://www.ctndatashare.org/. Over 300 research scientists have downloaded one or more data sets. These data sets are in compliance with HIPAA and CDISC (Clinical Data Interchange Standards Consortium) standards in support of the interoperability required by the NIH Roadmap.

International Program-Related Publications

New INVEST/CTN Fellowship Flyer Available
NIDA IP has developed a new flyer to help expand recruitment efforts for its INVEST/CTN Research Fellowship program. The colorful flyer describes the goals of the program and answers commonly asked questions about what the fellowship includes, who is eligible, how to find a mentor, and how and when to apply. A downloadable PDF version of the flyer is available on the International Program's Web site at http://www.international.drugabuse.gov/research/PDFs/CTN_flyer_110909.pdf.

Other Publications

Bjork JM, Chen G, Smith AR, Hommer DW. Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescents. J Child Psychol Psychiatry. 2009 December. [Epub ahead of print].

Schulden JD, Thomas YF, Compton WM. Substance abuse in the U.S.: findings from recent epidemiological studies. Current Psychiatry Reports 2009;11:353-359.

Lopez M, Compton WM, Volkow ND. Changes in cigarette and illicit drug use among US teenagers. Archives of Pediatrics and Adolescent Medicine 2009;163(9):869-870.

Grant BF, Goldstein RB, Chou SP, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Molecular Psychiatry 2009;14:1051-1066.

Chandler R, Dennis M, El-Bassel N, Schwartz R, Field G. Ensuring safety, implementation, and scientific integrity of clinical trials: Lessons from the Criminal Justice-Drug Abuse Treatment Studies Data & Safety Monitoring Board. Journal of Experimental Criminology 2009;5(3):323-344.

Jones DJ, Roberts GW. Substance Abuse, HIV and Mental Health Issues: Prevention and Treatment Challenges. In: Stone, V. Ojikutu, B.O. (eds.) HIV/AIDS in U.S. Communities of Color, New York: Springer, pp. 228-244, 2009.

Ducharme LJ, Roman PM. Consideration of site characteristics may be important in the development of dissemination materials and local constraints on the uptake of evidence-based practices. Opioid Treatment Programs in the Clinical Trials Network: Representativeness and Buprenorphine Adoption. J Subst Abuse Treat. 2009;37:90-94.

Diana A. "Blending Sociology with Federal Funding: The example of the National Institutes of Health Small Business Innovative Research Program," in doing sociology: Case studies in sociological practice. Edited by Jammie Price, Roger A. Straus, and Jeffrey R. Breese, Rowan and Littlefield Publishers, Inc., 2009.

Barr CS*, Chen SA*, Schwandt ML, et al. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry 2010 Jan 1;67(1):78-80. [*contributed equally]

Montoya ID, McCann D. Drugs of Abuse: Management of intoxication and antidotes. In: Textbook of Toxicology: Molecular, Clinical and Environmental Toxicology. Volume 2: Clinical Toxicology. Luch, Andreas (Ed.). 2009.

Khalsa J, Elkashef A. Drug Interactions between antiretroviral medications and medications used in the treatment of drug addiction: Research needs. Amer J Addictions 2009;19:96-100.

NIH HMP Working Group, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res. 2009 Dec; 19(12):2317-2323.

Do Carmo GP, Folk JE, Rice KC, et al. The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol. 2009 Feb 14;604(1-3):58-65.

De Bruyne S, Boos TL, Wyffels L, et al. Synthesis, radiosynthesis and in vivo evaluation of [123I]-4-(2-(Bis(4-Fluorophenyl) methoxy)ethyl)-1-(4-Iodobenzyl)piperidine as a selective tracer for imaging the dopamine transporter. J Labelled Comp Radiopharm. 2009;52:304-311.

Lang L, Ma Y, Kim BM, et al. [76Br]BMK-I-152, A non-peptide analogue for PET imaging of corticotropin-releasing hormone type 1 receptor (CRHR1). J Labelled Comp Radiopharm. 2009;52:394-400.

Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83-85.

Hutchinson MR, Ramos KM, Loram LC, et al. Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats. Neuroscience. 2009 Dec 29;164(4):1821-1832.

Kreibich AS, Cleck JN, Rice KC, Blendy JA. Stress induced potentiation of cocaine reward is dependent on CRF1 receptor and CREB. Neuropsychopharmacol. 2009; 34:2609-2617.

Li JX, Unzeitig A, Javors MA, Rice KC, Koek W, France CP. Discriminative stimulus (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats. J Pharmacol Exp Ther. 2009 Nov;331(2):671-679.

Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "Toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends in Pharml. Sci. 2009;30:581-591.

Lewis SS, Hutchinson MR, Rezvani N, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β.Neurosci. 2009;165:569-583.

Cottone P, Sabino V, Roberto M, et al. CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20016-20.

Iyer MR, Lee YS, Deschamps JR, et al. Probes for narcotic receptor mediated phenomena. 40. N-substituted Cis-4a-Ethyl-1,2,3,4,4a,9a-Hexahydrobenzofuro[2,3-c]Pyridin-8-ols. Bioorg. Med. Chem. Epub 2009 Nov 18.

Tanda G, Newman AH, Katz JL. Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. In: Contemporary Drug Discovery (S.J. Enna and M. Williams, eds.) Advances in Pharmacology, 57, 2009.

Hiranita T, Soto PL, Tanda G, Katz JL. Reinforcing effects of σ-receptor agonists in rats trained to self-administer cocaine. JPET Fast Forward. DOI:10.1124/jpet.109.159236.

Airavaara M, Shen H, Kuo CC, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) reduces ischemic brain injury and promotes behavioral recovery in rats. J Comp Neurol 2009; 515:116-124.

Borlongan CV, Hayashi T, Oeltgen PR, et al. Hibernation-like state induced by an opioid peptide protects against experimental stroke. BMC Biol 2009; 7:31.

Harvey BK, Chou J, Shen H, Hoffer BJ, Wang Y. Diadenosine tetraphosphate reduces toxicity caused by high-dose methamphetamine administration. Neurotoxicology 2009; 30:436-444.

Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserve primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009;106:1285-1290.

Luo Y, Kuo CC, Shen H, et al. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann Neurol 2009; 65:520-530.

Luo Y, Hoffer BJ, Wang Y. Rotation, Drug-induced. The Encyclopedia of Movement Disorders (MOVE).1 ed. London: Elsevier, 2009.

Shen H, Luo Y, Kuo CC, et al. 9-Cis-Retinoic acid reduces ischemic brain injury in rodents via bone morphogenetic protein. J Neurosci Res 2009; 87:545-555.

Shen H, Kuo CC, Chou J, et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J 2009; 23:1958-1968.

Shen H, Hoffer BJ, Wang Y. Restoration of nigrostriatal pathway in Parkinson's animals by the bridge transplantation technique. J Exp Clin Med 2009; 1:12-16.

Yu S, Kaneko Y, Bae E, et al. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain Res 2009;1287:157-163.

Taylor M, Grundt P, Griffin SA, et al. Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse, 2009;64:251-266.

Tanda G, Newman AH, Ebbs AL, et al. Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther, e-pub May 29, 2009.

Besson M, Belin D, McNamara R, et al. Dissociable control of impulsivity by dopamine D2/3 receptors in the core and shell sub-regions of the rat nucleus accumbens. Neuropsychopharmacology, e-pub October 21, 2009.

Baladi MG, Newman AH, France CP. Dopamine D3 receptors mediate the discriminative stimulus effects of quinpirole in free-feeding rats. J Pharmacol Exp. Ther. e-pub October 1, 2009.

Tanda G, Newman AH, Katz JL. Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Contemporary Drug Discovery in Adv. Pharmacol, 57, 2S. J. Enna and M. Williams, Eds.: 2009, 253-89. Invited review.

Schwilke EW, Schwope DM, Karschner EL, et al. δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC and 11-nor-9-Carboxy-THC plasma pharmacokinetics during and following continuous high-dose oral THC. Clin Chem. 2009 Dec; 55(12):2180-2189. Epub 2009 Oct 15.

Karschner EL, Schwilke EW, Lowe RH, et al. Do delta 9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009:104, 2041-2048.

Lowe RH, Abraham TT, Darwin WD, et al. Extended urinary delta 9 tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alc Depend 2009;105:24-32.

Karschner EL, Schwilke EW, Lowe RH, et al. Implications of Plasma δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC and 11-Nor-9-carboxy-THC Concentrations in Chronic Cannabis Smokers. J Anal Toxicol, 2009 Oct;33(8): 469-477.

Brunet BR, Barnes AJ, Choo RE, et al. Monitoring pregnant women's illicit opiate and cocaine use with sweat testing. Ther Drug Monitor. 2009 Nov 18 (Epub ahead of print). PMID: 19927046.

Bosker WM and Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009 Nov; 55(11):1910-1931. Epub 2009. Sep 10.

de Castro A, Concheiro M, Shakleya DM, Huestis MA. Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. J Chrom B 2009 Oct 1: 877(27):3065-3071.

Gray TR, Lagasse LL, Smith LM, et al. Identification of Prenatal Amphetamines Exposure by Maternal Interview and Meconium Toxicology in the Infant Development, Environment and Lifestyle (IDEAL) Study. Ther Drug Monitor 2009;31(6):769-775.

de Castro A, Concheiro M, Shakleya DM, Huestis MA. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography mass spectrometry. J Anal Toxicol 2009 Jun;33(5):243-252.

Shakleya, DM, Huestis MA. Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. J Chrom B, 2009 Nov 1; 877(29): 3537-3542.

Baumann MH, Zolkowska D, Kim I, et al. Effects of dose and route of administration on pharmacokinetics of ()-3,4-methylenedioxymethamphetamine (MDMA) in the rat. Drug metabolism disposition, 2009 Nov; 37(11): 2163-2170.

Abraham TT, Barnes AJ, Lowe RH, et al. Urinary MDMA, MDA, HMMA and HMA excretion following controlled MDMA administration to humans. J Anal Toxicol, 2009 Oct;33(8):439-446.

Hong LE, Gu H, Yang Y, et al. Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Archives Gen Psychiatry 2009;66:431-441.

Le Foll B, Chefer SI, Kimes AS, et al. Baseline expression of α4β2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biological Psychiatry 2009; 65:714-716.

Waltz JA, Schweitzer JB, Gold JM, et al. Patients with Schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharm 2009;34:1567-1577.

Hahn B, Ross TJ, Wolkenberg F, Huestis MA, Stein EA. Performance effects of nicotine during selective attention, divided attention and simple stimulus detection: an fMRI study. Cerebral Cortex 2009;19:1990-2000.

Spinelli S, Chefer S, Suomi SJ, Higley D, Barr CS, Stein EA. Early life stress induces long-term morphological changes in primate brain. Arch Gen Psych. 2009;66:658-665.

Hong LE, Schroeder M, Ross TJ, et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophrenia Bulletin, Advance Access published on August 27, 2009.

Baumann MH, Rothman RB Neural and cardiac toxicities associated with 3,4-methylenedioxy-methamphetamine (MDMA). Int Rev Neurobiol. 2009;88:257-296.

Baumann MH, Zolkowska D, Kim I, et al. Effects of Dose and Route of Administration on Pharmacokinetics of ({+/-})-3,4-Methylenedioxy-methamphetaml.ine (MDMA) in the Rat. Drug Metab Dispos. 2009;37:2163-2170.

Fontana G, Savona G, Rodriguez B, et al.. Synthetic studies on neoclerodane diterpenes from Salvia splendens: oxidative modifications of ring A. Tetrahedron 2009;65:1708-1715.

Hendricks EJ, Rothman RB, Greenway FL How Physician Obesity specialists use drugs to treat obesity. Obesity, Silver Spring, MD, 2009.

Negus SS, Baumann MH, Rothman RB, et al. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther. 2009;329:272-281.

Pelotte AL, Smith RM, Ayestas M, et al. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009;19: 2811-2814.

Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009;8:317-329.

Rothman RB, Dersch CM, Ananthan S, Partilla JS Studies of the Biogenic Amine Transporters. 13. Identification of "Agonist" and "Antagonist" Allosteric Modulators of Amphetamine-Induced Dopamine Release. J Pharmacol Exp Ther. 2009;392:718-728.

Sally EJ, Xu H, Dersch CM, et al. Identification of a novel "almost neutral" mu-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse 2009;64:280-288.

Simpson DS, Lovell KM, Lozama A, et al. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors. Organic & Biomolecular Chemistry 2009;7:3748-3756.

Wellman PJ, Davis KW, Clifford PS, Rothman RB, Blough BE Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug Alcohol Depend. 2009;100:234-239.

Zhang Y, Lee YS, Rothman RB, et al. Probes for narcotic receptor mediated phenomena. 39.1 Enantiomeric N-substituted benzofuro[2,3-c]pyridin-6-ols:synthesis and topological relationship to oxide-bridged phenylmorphans2. J Med Chem. 2009;52:7570-7579.

Lin JL, Vahabzadeh M, Mezghanni M, Epstein DH, Preston KL. A usability study of transactional electronic diary: results from expert evaluation to participants use. AMIA Annu Symp Proc. 2009: 937.

Wise RA, Morales M. A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Res 2009 [Epub ahead of print]

Wise RA. Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction. Trends Neurosci. 2009;32(10):517-524.

Suto N, Ecke LE, Wise RA. Control of within-binge cocaine-seeking by dopamine and glutamate in the core of nucleus accumbens. Psychopharmacology (Berl). 2009;205(3):431-439.

Wang B, You ZB, Wise RA. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry. 2009;15;65(10):857-862.

Kiyatkin EA, Smirnov MS. Rapid EEG desynchronization and EMG activation induced by intravenous cocaine in freely moving rats: a peripheral, non-dopamine neural triggering. Am J Physiol Regul Integr Comp Physiol. 2009 [Epub ahead of print]

Smirnov MS, Kiyatkin EA. Phasic and tonic fluctuations in brain, muscle, and skin temperatures during motivated drinking behavior in rats: Physiological correlates of motivation and reward. Brain Res. 2009 Nov 22. [Epub ahead of print]

Kiyatkin EA, Sharma HS. Acute methamphetamine intoxication brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int Rev Neurobiol. 2009;88:65-100.

Smirnov MS, Kiyatkin EA. Cocaine action on peripheral, non-monoamine neural substrates as a trigger of electroencephalographic desynchronization and electromyographic activation following i.v. administration in freely moving rats. Neuroscience. 2009 Oct 25. [Epub ahead of print]

Kiyatkin EA, Sharma HS.Permeability of the blood-brain barrier depends on brain temperature. Neuroscience. 2009 7;161(3):926-939.


Index

Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings

Publications

Staff Highlights

Grantee Honors

Get Adobe Reader



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal